Imaging test for kidney cancer using CD70-targeted drug
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial uses a special imaging drug that targets CD70 (a protein on some kidney cancer cells) to see if it can better detect and track kidney tumors. It may help doctors understand how much cancer is present and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been diagnosed with kidney cancer (especially clear cell or papillary type) or imaging suggests you might have it
- You are able to understand and sign a consent form agreeing to the study
- You are not pregnant
- You do not have severe liver or kidney problems
- You have not had major surgery in the last month
- You are not allergic to antibody-based imaging drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cell-based treatment designed to target kidney cancer cells that have a protein called CD70. The treatment involves collecting your immune cells, modifying them in the lab, and infusing them back to fight the cancer. It's for patients with advanced kidney cancer who have already tried at least one standard immunotherapy.
This study tests a new way to detect tumors by using a special injection that makes cancer cells visible on a PET scan. It may help people with renal cancer (especially clear cell type), lymphoma, or nasopharyngeal cancer.
This trial tests whether a special type of imaging scan (CD70-targeted PET/CT) can help doctors safely pause treatment in patients with advanced kidney cancer who respond well to standard immunotherapy and targeted therapy. The goal is to reduce unnecessary treatment while keeping the cancer controlled.
This trial is testing a new imaging agent called 18F-NY104 to see if it can help doctors see kidney cancer tumors on a PET/CT scan. If you have known or suspected kidney cancer that has spread or come back, this study may help find out if the tracer works for you.
This trial tests a new cell therapy (UCL70805F) that targets a protein called CD70 found on kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma who have tried standard treatments that are no longer working.
This study tests a new kind of PET scan that might better detect kidney cancer. It involves an injection of a special imaging agent and a scan to see if the cancer shows up clearly.
Hear when a new Urologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.